v3.23.3
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development, net of grants $ 4,441 $ 3,859 $ 12,260 $ 9,742
General and administrative 2,703 1,585 8,488 3,709
Total operating expenses 7,144 5,444 20,748 13,451
Loss from operations (7,144) (5,444) (20,748) (13,451)
Other income (expense), net 362 6,867 1,122 6,846
Net income/(loss) $ (6,782) $ 1,423 $ (19,626) $ (6,605)
Net income/(loss) per common share – basic $ (0.13) $ 0.04 $ (0.39) $ (0.18)
Net income/(loss) per common share – diluted $ (0.13) $ 0.04 $ (0.39) $ (0.18)
Weighted average common shares outstanding – basic 50,837 37,965 50,757 37,712
Weighted average common shares outstanding – diluted 50,837 38,477 50,757 37,712

Source